

December 23, 2015

Attention: Branch Managers/ Purchase Managers

Subject: Cal.D.Forte - 1.25 mg Colecalciferol BP, Equivalent 50,000 I.U Vitamin D3

(Pharmacode: 2193000)

This product has been approved & sold under a provisional consent from Medsafe since the 10th of February, 2000.

From 12 February 2016, this provisional consent will expire and the product will no longer be an approved medicine.

The product can still be prescribed through a Section 29 application, but Medsafe have indicated to API that they do not intend to further extend the provisional consent of Cal.D.Forte.

New Product: API has spent that last 4 years developing a new formulation, in tablet form, for 1.25 mg Colecalciferol BP, Equivalent 50,000 I.U Vitamin D3. We have also been recently granted a Patent on this product. We are currently in the final stages of the New Medicine Application with Medsafe and anticipate approval in the first half of 2016.

Current action recommendation:

We recommend that you carefully manage your stockholdings, with a view to running down your stocks as we approach the product deregistration on the 12th of February.

While the information on this product deregistration is not new, we want to remind all the wholesalers of this action so that they carefully manage their stockholdings and are not caught with excess stock post the 12th of February.

API will not be taking back excess product for refunds.

Regards



Mitch Cuevas

General Manager

API Consumer Brands (PSM Healthcare Ltd)

14-16 Norman Spencer Drive. P.O. Box 76 401
Manukau City. Auckland 2241, New Zealand
T: +64 9 279 7979 F: +64 9 279 7999

PSM Healthcare Ltd trading as API Consumer Brands

www.api.nel.nz